Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Fecal Microbiota
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Recipient : Gabrail Cancer Center Research
Deal Size : Inapplicable
Deal Type : Inapplicable
FMT for MDRO Colonization After Infection in Renal Transplant Recipients
Details : Fecal Microbiota is a Probiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Drug Resistance, Microbial.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
October 04, 2016
Lead Product(s) : Fecal Microbiota
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Recipient : Gabrail Cancer Center Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Recipient : Institut Claudius Regaud
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This drug candidate is currently being evaluated in clinical studies for the treatment of Non-Muscle Invasive Bladder Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 09, 2016
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : Institut Claudius Regaud
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
